Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study
Open Access
- 8 May 2012
- journal article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 106 (11), 1722-1727
- https://doi.org/10.1038/bjc.2012.153
Abstract
Background: Methods: Results: Conclusion:Keywords
This publication has 14 references indexed in Scilit:
- A Phase I Dose–Escalation Study of Regorafenib (BAY 73–4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid TumorsClinical Cancer Research, 2012
- 7141 POSTER Phase II Trial of the Oral Multikinase Inhibitor Regorafenib (BAY 73-4506) as First-line Therapy in Patients With Metastatic or Unresectable Renal Cell Carcinoma (RCC)European Journal Of Cancer, 2011
- Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activityInternational Journal of Cancer, 2010
- Abstract 1666: Regorafenib (BAY 73-4506): preclinical pharmacology and clinical identification and quantification of its major metabolitesCancer Research, 2010
- Evolving Treatment of Advanced Colorectal CancerCurrent Oncology Reports, 2010
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal Of Cancer, 2009
- DCE-MRI assessment of the effect of vandetanib on tumor vasculature in patients with advanced colorectal cancer and liver metastases: a randomized phase I studyJournal of Angiogenesis Research, 2009
- An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapyAnnals Of Oncology, 2007
- Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal CancerJournal of Clinical Oncology, 2007
- Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal CancerNew England Journal of Medicine, 2004